BE without fail? R vs. R! Become a billion­aire! [Off Topic]

posted by Helmut Homepage – Vienna, Austria, 2013-05-31 17:17 (3064 d 01:54 ago) – Posting: # 10704
Views: 10,633

Hi Outlaw!

» […] Scientific malfeasance


[image]Now get a decent cup of tea, sit down, read this story and the follow up. Details given by the US Department of Justice and :blahblah: [image] archived from Ranbaxy’s website.

   »Company scientists told Thakur’s staff that they were directed to […] substitute brand-name drugs in lieu of their own ge­nerics in bio­equi­va­lence tests to produce better results.«
   »And then there was the ultimate shortcut: using brand-name drugs as stand-ins for its own in bioequivalence studies.«
   »Ranbaxy executives didn’t care, says Kathy Spreen, and made little effort to conceal it. In a con­ference call with a dozen company executives, one brushed aside her fears about the quality of the AIDS medicine Ranbaxy was supplying for Africa. “Who cares?” he said, according to Spreen. “It’s just blacks dying.”«

Makes me sick. :vomit:

BTW, in 2008 these guys cashed $2 billion by selling their 34% stake to Daiichi Sankyo. Enough for each of them to buy Ferrari 458 Spiders every single week for the rest of their lives!
Given their chutzpah, I’m sure they would succeed in negotiating a discount.

Edit: In 2014–2015 Daiichi Sankyo gave up sorting out this mess (seemingly to accept an $800 million loss was considered cheaper than to continue) and sold to Sun Pharma making it the largest Indian pharma company and the 5th largest generic company worldwide. Do you think that Sun can/will do better than the Japanese?

Dif-tor heh smusma 🖖
Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

 Admin contact
21,749 posts in 4,547 threads, 1,545 registered users;
online 13 (0 registered, 13 guests [including 5 identified bots]).
Forum time: Wednesday 19:11 CEST (Europe/Vienna)

Mediocrity finds safety in standardization.    Frederick E. Crane

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz